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The ESCRT pathway mediates membrane remodel-
ing during enveloped virus budding, cytokinesis,
and intralumenal endosomal vesicle formation. Late
in the pathway, a subset of membrane-associated
ESCRT-III proteins display terminal amphipathic
‘‘MIM1’’ helices that bind and recruit VPS4 ATPases
via their MIT domains. We now report that VPS4
MIT domains also bind a second, ‘‘MIM2’’ motif
found in a different subset of ESCRT-III subunits.
The solution structure of the VPS4 MIT-CHMP6
MIM2 complex revealed that MIM2 elements bind in
extended conformations along the groove between
the first and third helices of the MIT domain. Muta-
tions that block VPS4 MIT-MIM2 interactions inhibit
VPS4 recruitment, lysosomal protein targeting, and
HIV-1 budding. MIT-MIM2 interactions appear to be
common throughout the ESCRT pathway and pos-
sibly elsewhere, and we suggest how these inter-
actions could contribute to a mechanism in which
VPS4 and ESCRT-III proteins function together to
constrict the necks of budding vesicles.
INTRODUCTION
The human ESCRT pathway helps facilitate membrane fission
events required during enveloped virus budding, the abscission
stage of cytokinesis, and intralumenal vesicle formation at the
multivesicular body (MVB) (Bieniasz, 2006; Hurley, 2008; Sak-
sena et al., 2007; Williams and Urbe, 2007). Most ESCRT path-
way members function as subunits of one of four multiprotein
complexes, termed ESCRT-0, -I, -II, and -III. The pathway
also has a multiprotein ATPase complex, which is organized
by the dodecameric VPS4 enzyme and is recruited to sites of
action through direct interactions with ESCRT-III subunits
(Babst et al., 1998; Obita et al., 2007; Stuchell-Brereton et al.,
2007). Although mechanistic details are lacking, there is in-
creasing evidence that the ESCRT-III and VPS4 complexes
may act in concert to help create and constrict the thin mem-
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and MVB vesicle formation.
Human cells express a total of 11 ESCRT-III or chargedmulti-
vesicular body (CHMP) proteins, which can be subdivided into 7
different families (CHMP1–7). The CHMP1–6 families corre-
spond to the six ESCRT-III-like proteins in S. cerevisiae, whereas
CHMP7 has no yeast ortholog (Horii et al., 2006). ESCRT-III sub-
units copolymerize at sites of action (Babst et al., 2002), and re-
cent evidence indicates that ESCRT-III subunits of the CHMP4
family can form circular filaments around sites of membrane ex-
vagination (Hanson et al., 2008). Crystallographic analyses have
revealed that the core of another ESCRT-III subunit, CHMP3,
is organized about an extended helical hairpin that is capped
at one end by three smaller helices (Muziol et al., 2006). All
CHMP proteins have related sequences and presumably adopt
similar folds, but have evolved distinct activities, particularly in
cofactor recruitment. For example, specific ESCRT-III subunits
bind more tightly to the VPS4 ATPases (Stuchell-Brereton
et al., 2007), the VPS4 activator Vta1p/LIP5 (Azmi et al., 2008;
Shim et al., 2008; Xiao et al., 2008), the adaptor protein ALIX
(CHMP4A-C) (McCullough et al., 2008), and the ubiquitin hydro-
lases AMSH (CHMP1A and 3) and UBPY (CHMP1A, 1B, 2A, 4C,
and 7) (Row et al., 2007). In all well-characterized cases, these
cofactors are recruited by amphipathic helices located at or
near the CHMP C termini. VPS4A, VPS4B, AMSH, UBPY, and
Vta1p/LIP5 (but not ALIX) all use microtubule interacting and
transport (MIT) domains to bind these ESCRT-III recognition he-
lices, which are termed MIT interacting motifs (MIM) (Hurley and
Yang, 2008). Remarkably, the VPS4 ATPase complex apparently
contains 24 MIT domains, 1 from each of the 12 VPS4 subunits
and 2 from each of the 6 associated Vta1p/LIP5 cofactors
(Azmi et al., 2008; Xiao et al., 2008; Yu et al., 2008). Thus, it ap-
pears that ESCRT-III filaments present a polymeric array of MIM
elements that recruit VPS4 and other MIT-domain-containing
proteins to complete the terminal events of the ESCRT pathway.
Recent structural studies have revealed that MIT domains are
asymmetric three-helix bundles that bind amphipathic MIM heli-
ces along the groove between MIT helices 2 and 3 (Obita et al.,
2007; Stuchell-Brereton et al., 2007). Molecular recognition is
mediated by three MIM leucine/hydrophobic residues and by
flanking hydrophilic residues that make favorable interactions
along the MIT groove. It was therefore surprising that our initial
surveys of VPS4-ESCRT-III protein interactions revealed that
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Structure and Functions of Vps4 MIT-MIM2 ComplexesVPS4A and VPS4B bind several human CHMP4–6 proteins (von
Schwedler et al., 2003 and data not shown), even though these
ESCRT-III subunits lack C-terminal MIM consensus sequences.
We therefore characterized the tightest of these complexes, the
CHMP6-VPS4A complex, and have discovered that MIT do-
mains can bind their targets through a second type of interaction
that is entirely distinct from the canonical MIM-MIT interaction.
The 3D structure and functional importance of this newMIT inter-
action mode are reported.
RESULTS
Mapping the CHMP6-VPS4 MIT Domain Interaction
Biosensor binding assays showed that pure recombinant VPS4A
MIT domain bound the immobilized GST-CHMP6 protein with
a dissociation constant of KD = 33 ± 7 mM (Figure 1), which is
similar to the affinities of other well-characterized VPS4 MIT-
ESCRT-III interactions (Obita et al., 2007; Stuchell-Brereton
et al., 2007). As noted above, however, the CHMP6 terminus
does not conform to the MIM consensus, and removing the final
20 CHMP6 residues actually increased VPS4A MIT binding af-
finity slightly (KD = 23.2 ± 0.2 mM), indicating that the VPS4A
MIT-CHMP6 interaction must differ from all VPS4-ESCRT-III
interactions characterized to date.
Deletion analyses were used to map the VPS4A MIT binding
site to an internal sequence spanned by CHMP6 residues 170–
181 (Figures 1B and 1C, and see Table S1 available online for
all measured dissociation constants). Optimal binding was
observed for the CHMP6165–181 fragment (KD = 5.8 ± 0.8 mM),
and strong binding was also observed for the minimal
CHMP170–181 fragment (KD = 8 ± 0.1 mM). Importantly, VPS4A
Figure 1. VPS4A MIT Binds a Unique Inter-
nal CHMP6 MIT Interacting Motif, MIM2
(A) Biosensorgrams showing concentration-de-
pendent binding of purified VPS4A MIT (residues
1–84, 0–500 mM) to full-length GST-CHMP61201.
(B) Biosensor binding isotherms showing VPS4A
MIT binding to a series of different GST-CHMP6
deletion mutants (see inset key). Binding to a
GST control surface was negligible (not shown).
(C) Schematic illustration of the predicted CHMP6
secondary structure, indicating the location of the
CHMP6 MIM2 between helices a4 and a5. Disso-
ciation constants for the different CHMP6 con-
structs are shown at right.
MIT bound to these smaller CHMP6
fragments 5-fold more tightly than to
the full-length protein, which is consistent
with the observation that full-length
ESCRT-III proteins fold into ‘‘autoinhi-
bited’’ conformations that can mask pro-
tein binding sites (Lata et al., 2008; Lin
et al., 2005). The VPS4A binding site
on CHMP6 is conserved across eukary-
otic CHMP6 proteins (Figure 2A and see
Table S2), but the sequence is rich in pro-
lines and does not exhibit significant helical propensity, again
indicating a novel MIT binding mode.
Structure of the VPS4A-CHMP6 MIM2 Complex
To visualize how VPS4 recognizes CHMP6, we determined the
solution structure of the VPS4A MIT domain in complex with its
CHMP6166–181 binding site. Nuclear magnetic resonance spec-
troscopy (NMR) spectra of the 1:1 complex were of high qual-
ity, and backbone heavy atoms in the ordered core of the 20
lowest penalty complexes overlaid with low root mean squared
deviation (rmsd) values (0.34 ± 0.06 A˚), indicating that the struc-
ture was well defined (see Figures S1 and S2, and Table 1). As
shown in Figure 2B (right panel), VPS4A MIT formed the
expected three-helix bundle and did not change structure
significantly upon CHMP6 binding. The CHMP6166–181 element
bound in an extended conformation along the groove between
MIT helices 1 and 3, burying 1300 ± 150 A˚2 of solvent-exposed
surface. The CHMP6166–181 binding mode is therefore entirely
different from previously characterized MIM-MIT interactions
(compare right and left panels in Figure 2B). We have desig-
nated this new binding element a type-2 MIT Interacting Motif
(MIM2).
As shown in Figure 2, the CHMP6166–181 MIM2 peptide is ori-
ented parallel to MIT helices 1 and 3, and tracks in an extended
but irregular conformation along the MIT helix 1/3 groove for
most of its length until a kink at CHMP6 residue Pro177 orients
the more mobile C-terminal residues (177–179) over the top of
the MIT helical bundle. The structure of a yeast Vps4p MIT-
Vps2p complex also showed a proline-rich sequence binding
in the helix 1/3 groove of the MIT domain (in addition to a canon-
ical MIM1-MIT interaction made by the Vps2p terminus; Obita
et al., 2007). Although the VPS4 MIT-CHMP6166–181 and Vps4p
Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc. 63
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Structure and Functions of Vps4 MIT-MIM2 ComplexesFigure 2. Solution Structure of the VPS4A MIT-CHMP6 MIM2 Complex
(A) Graphic summary showing MIM2 residues that are >50% conserved across eukaryotic CHMP6 proteins (and see Table S2), the resulting MIM2 consensus
sequence, and the human CHMP6 MIM2 sequence. (F) denotes an aliphatic residue and (-) denotes acidic residues.
(B) Structures of human VPS4A MIT in complex with the MIM1 element from CHMP1A (left structure, MIM1 helix in green) and the CHMP6 MIM2 element (right,
MIM2 strand in blue). The MIT domains are shown in the same orientation to emphasize that the MIM1 and MIM2 elements bind in different grooves of the MIT
three-helix bundle. Key MIM contact residues are shown explicitly in both structures.
(C and D) Overview (C) and detailed views (D) of the VPS4A MIT domain (gray and black, space filling representation) in complex with the CHMP6 MIM2 element
(stick representation, blue). Key side chains on both sides of the interface are shown in (D), with selected intermolecular salt bridges and hydrogen bonds
indicated by dashed lines.MIT-VPS2183–232 structures share some similarities in binding
proline side chains in the MIT helix 1/3 groove, Obita et al. con-
cluded that the proline interactions were crystal packing artifacts
because the Vps4p MIT binding affinity was not reduced when
the proline-rich Vps2p sequence was removed. We agree with
this interpretation because the binding orientation of the Vps2p
strand is opposite that seen here for the CHMP6166–181 MIM. Im-
portantly, the orientation of the MIM2 element in our structure
matches the orientation of a MIM1 element (i.e., both elements
bind parallel to MIT helix 3), which enables MIT domains to
bind different ESCRT-III subunits in the same relative orientation.
The VPS4A MIT-CHMP6166–181 structure, together with se-
quence and mutational analyses described below, indicates
that the central 170LP(E/D)VP174 CHMP6 sequence forms the
core of the MIM2 element, with flanking residues also contribut-
ing binding affinity and specificity. The helix 1/3 groove is gener-
ally hydrophobic, but there is a salt bridge between MIT Arg66
and Glu20 at the top of the groove that remains intact in the com-
64 Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc.plex and is partially buried by peptide binding. As shown in
Figure 2D, a series of CHMP6166–181 side chains project toward
the MIT domain, and CHMP6 residues Ile168, Leu170, Pro171,
Val173, Pro174, and Leu178 each make well-defined hydro-
phobic interactions along the groove. All of these MIM2 resi-
dues are conserved in identity or hydrophobic character across
metazoan CHMP6 MIM2 proteins (Figure 2A and Figure S2),
and the importance of the Leu170, Val173, and Leu178 interac-
tions was confirmed by mutagenesis (see below). In addition,
the MIT Lys59 and Tyr63 side chains form hydrogen bonds to
the carbonyl oxygen of CHMP6 Pro171, which help stabilize
the MIT-MIM2 core, and the CHMP6 Glu176 side chain also
forms a salt bridge with MIT Lys23, which explains the conser-
vation of this acidic MIM2 residue. In contrast, the hydrophilic
CHMP6 Glu169, Glu172, and Ser175 residues all project into
solution, and the conservation of the two acidic residues is
not explained by the structure, except insofar as these residues
contribute to complex solubility.
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Mutational analyses were performed to assess the energetic
contributions of the CHMP6 MIM2 Leu170, Val173, and
Leu178 residues and to identify nonbinding mutants for use
in functional studies. As shown in Figure 3A, the CHMP6
Leu170Asp and Val173Asp mutations eliminated all detectable
VPS4A MIT binding, whereas the Leu178Asp mutation reduced
binding affinity 8-fold. These data confirm the importance of
the core MIM2 Leu170 and Val173 residues, and demonstrate
that the flanking Leu178 residue, though not essential, also con-
tributes to VPS4A MIT binding.
Point mutations in the two different VPS4A MIT binding sur-
faces were also examined to identify MIT mutations that could
Table 1. Structural Statistics for VPS4A MIT-CHMP6166–181
NMR Distance and Dihedral Constraints
Distance
constraints
total NOE 3353
intraresidue 600
intramolecular 3193
sequential (ji – jj = 1) 841
medium-range (2R ji – jj < 5) 963
long-range (ji – jjR 5) 789
intermolecular (MIT – CHMP6) 160
hydrogen bonds 57
Dihedral angle
constraints
total dihedral angle restraints 140
f 70
c 70
Dipolar coupling
constraints
1DNH (VPS4A MIT only) 62
Structure Statistics
Violations (mean, s.d.) distance constraints (A˚) 0.047, 0.002
dihedral angle constraints () 0.356, 0.045
1DNH dipolar coupling
constraints (Hz)
0.879, 0.170
max. distance
constraint violation (A˚)
0.52
max. dihedral
angle violation ()
5.5
max. dipolar
coupling violation (Hz)
1.7
Deviations from
idealized geometry
rmsd
bond lengths (A˚) 0.005
bond angles () 0.55
impropers () 0.515
Average pairwise
rmsda (A˚)
all heavy atoms 0.98 ± 0.06
backbone atoms (Ca, C, N, O) 0.34 ± 0.06
Ramachandran statistics
(% of residues)
favored, additionally
allowed, generously allowed
97, 3, 0
a Average pairwise rmsd was calculated from the 20 lowest-energy
XPLOR-NIH structures superimposed with main chain atoms of VPS4A
residues 5–75 and CHMP6 residues 168–178.discriminate between the MIM1 and MIM2 binding modes.
These experiments tested VPS4A MIT binding to (1) the
CHMP6 MIM2 element and (2) the well-characterized MIM1 ele-
ment at the C terminus of human CHMP1B (Stuchell-Brereton
et al., 2007). As shown in Figure 3B, the VPS4A Val13Asp muta-
tion, which sits in the center of theMIM2 binding groove, blocked
all detectable CHMP6 binding (compare light and dark curves
with triangular symbols). Importantly, this residue did not reduce
CHMP1B binding affinity (compare light and dark curves with
oval symbols). Conversely, as shown in Figure 3C, a mutation
within the VPS4A MIM1 binding site (Leu64Asp) blocked all de-
tectable CHMP1B MIM1 binding, although this mutation also
modestly reduced the affinity of CHMP6MIM2 (4-fold reduction).
This affinity reduction may arise because Leu64 is adjacent to
Tyr63, which hydrogen bonds to the backbone carbonyl of
CHMP6 Pro171. Nevertheless, these experiments identify
VPS4A MIT mutations that can discriminate between the MIM1
and MIM2 binding modes and, in particular, demonstrate that
the Val13Asp mutation blocks MIM2 binding without affecting
the binding of a control MIM1 element.
MIM2 Binding Helps Recruit VPS4
to Class E Compartments
VPS4 ATPases are targeted to endosomal membranes via MIT
domain interactions (Babst et al., 1998), and we therefore tested
whether the MIM2 binding site on the MIT domain contributes to
VPS4 recruitment. Endosomal localization is most easily visual-
ized for VPS4 proteins that lack ATPase activity because these
proteins are recruited, but not released, from the surfaces of ab-
errantly enlarged endosomes (termed ‘‘class E’’ compartments).
This phenomenon is illustrated in Figure 4, where the wild-type
GFP-VPS4A protein was distributed diffusely in 91% ± 2% of
cells analyzed, whereas a GFP-VPS4AK173Q mutant, which is im-
paired in ATP binding, exhibited punctate class E compartment
localization in 80% of the cells (Figure 4A, compare upper right
and left panels; and Figure 4B, compare lanes 1 and 5). As re-
ported previously, the Leu64Asp MIT mutation, which primarily
blocks MIM1 interactions, inhibited recruitment so that the
GFP-VPS4AK173Q,L64D double mutant exhibited diffuse cytoplas-
mic distributions in 81%± 7%of cells (Figure 4A, lower left panel;
and Figure 4B, lane 6; Stuchell-Brereton et al., 2007). Impor-
tantly, the Val13Asp mutation in the VPS4A MIM2 binding site
also inhibited class E compartment localization, resulting in a dif-
fuse distribution of the GFP-VPS4AK173Q,V13D double mutant in
80% ± 4% of cells (Figure 4A, lower right panel; and Figure 4B,
lane 7). Not surprisingly, the GFP-VPS4AK173Q,V13D,L64D triple
mutant was recruited to class E compartments even less effi-
ciently, resulting in diffuse cytoplasmic distributions in 86% ±
3% of cells (Figure 4B, lane 8). These experiments indicate that
both MIM1 and MIM2 interactions contribute in recruiting
VPS4A to endosomal membranes.
The CHMP6 MIM2 Binding Site Is Required
for Ferroportin Degradation
Several ESCRT functions, including HIV budding, are insensitive
to CHMP6 depletion (Langelier et al., 2006). We have shown,
however, that lysosomal degradation of ferroportin, a plasma
membrane iron transporter, is impaired by CHMP6 depletion
(De Domenico et al., 2007). This system was therefore used to
Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc. 65
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portin trafficking through the MVB pathway. Treatment of wild-
type cells with the hormone hepcidin triggers ferroportin phos-
phorylation, endocytosis, ubiquitylation, endosomal trafficking,
MVB sorting, and lysosomal degradation. In the absence of
CHMP6, however, ferroportin can still be posttranslationally
modified and endocytosed, but not efficiently degraded because
it is not incorporated intoMVB vesicles. The protein therefore ac-
cumulates internally and can also be recycled back to the
plasma membrane (De Domenico et al., 2007). As shown in Fig-
ure 5, ferroportin-GFP was efficiently downregulated when en-
dogenous CHMP6 was depleted and replaced by comparable
levels of exogenously expressed, siRNA-resistant CHMP6-
Myc. Efficient depletion of endogenous CHMP6 is shown in
Figure 5A (compare lanes 1 and 2, upper panel), and hepcidin-in-
duced ferroportin downregulation in the presence of exogenous
CHMP6-Myc was analyzed either by western blot detection of
total cellular ferroportin-GFP (2.3-fold reduction in ferroportin
upon hepcidin treatment; compare lanes 7 and 8 in Figure 5B,
panel 2), or by total fluorescence intensity (compare panels 7
and 8 in Figure 5C; and quantified as a 4.2-fold fluorescence in-
tensity reduction in Figure 5D). In contrast, hepcidin-induced fer-
roportin downregulation was inhibited by two different CHMP6
MIM2 point mutations that blocked VPS4A MIT binding
(Leu170Asp and Val173Asp), as reflected by a lack of any ob-
servable ferroportin reduction in the western blot assays and re-
ductions of less than 40% in the fluorescence assays (Figures
Figure 3. Mutational Analyses of the VPS4A
MIT-CHMP6 Complex
(A) Biosensor binding isotherms showing VPS4A
MIT binding to wild-type and mutant CHMP6
MIM2 peptides (labeled). Note that the CHMP6
L178D mutation reduces the binding affinity 8-
fold (from KD = 5.8 ± 0.8 to KD = 44.4 ± 0.2 mM),
whereas the L170D and V173D mutations block
all detectable binding.
(B) Biosensor binding isotherms showing that the
V13D mutation in VPS4A MIT helix 1 blocks
CHMP6 MIM2 binding (triangles) but does not
affect CHMP1B MIM1 binding (ovals).
(C) Biosensor binding isotherms showing that the
L64D mutation in VPS4A MIT helix 3 blocks
CHMP1B MIM1 binding (ovals), but had a much
more modest effect on CHMP6 MIM2 binding (tri-
angles), altering CHMP6 MIM2 binding from KD =
5.8 ± 0.8 mM to KD = 26.1 ± 0.8 mM.
5B–5D, compare lanes 9 and 11 to lanes
10 and 12, respectively). Control experi-
ments behaved as expected, confirming
that all CHMP6-Myc constructs were ex-
pressed at similar levels (Figure 5B, panel
1, lanes 1–12), and that ferroportin down-
regulation occurred normally when the
CHMP6-Myc proteins were expressed in
the presence of endogenous CHMP6
(Figures 5B–5D, compare lanes 1, 3, and
5 to lanes 2, 4, and 6, respectively).
Thus, mutations in the CHMP6 MIM2 ele-
ment that block VPS4AMIT binding also block ferroportin down-
regulation, implying that the MIM2 element plays an essential
role when CHMP6 functions in MVB protein sorting.
The VPS4B MIM2 Binding Surface Is Required
for HIV-1 Budding
As discussed below, MIM2 elements appear in several other
proteins of the ESCRT pathway, suggesting that MIM2-MIT in-
teractions may be a central, recurring theme in ESCRT pathway
functions. To examine this idea, we tested the requirement for
VPS4B MIT-MIM2 interactions in HIV-1 budding. HIV budding
does not require CHMP6 (Langelier et al., 2006), and VPS4B
binds only very weakly to CHMP6 (KD = 786 ± 6 mM, Table S1).
We therefore reasoned that if mutations in the MIM2 binding
site of VPS4B MIT block virus budding, then additional MIM2-
MIT interactions must also be required for this ESCRT pathway
function, and presumably others as well.
These experiments again utilized an siRNA depletion/reconsti-
tution system that allowed us to test whether VPS4B mutants
could support HIV budding. siRNAs targeting both known human
VPS4 isoforms (A and B) were cotransfected, and this procedure
efficiently depleted both VPS4 proteins fromHEK293T cells (Fig-
ure 6, top two panels, compare lanes 1 and 2). As expected, de-
pletion of the two human VPS4 isoforms strongly inhibited HIV
releaseasmeasured in awesternblot assay (compare the release
of virus-associated CA and MA proteins in lanes 1 and 2, panel 5
[Virus]) and also by a reduction in viral titer in a single-cycle
66 Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc.
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ing Also Inhibit Recruitment of VPS4AK173Q to Class E Endosomal
Compartments
(A) Confocal fluorescence slices showing cellular distributions of wild-type
GFP-VPS4A (VPSAWT, upper left, negative control) and GFP-VPS4A proteins
with the following mutations: K173Q (upper right, positive control; mutation
blocks ATP binding and induces class E compartment formation),
K173Q,L64D (lower left; K173Q mutation blocks ATP binding and L64D muta-
tion blocks MIM1 binding), and K173Q,V13D (lower right; K173Q mutation
blocksATPbindingandV13DmutationblocksMIM2binding).Scalebar, 20mm.
(B) Quantification of cells showing diffuse cytoplasmic localization of wild-
type and mutant GFP-VPS4A proteins (mutations are listed on the x axis).
Two blinded sets of >100 cells of each type were scored. Error bars indi-
cate standard deviations. Note that the VPS4A MIT L64D and V13D muta-
tions both alleviate the class E compartment recruitment induced by the
K173Q mutation (compare lanes 6–8 to lane 5).replication assay (Figure 6, graph at bottom; compare lanes
1 and 2, 18-fold reduction in titer; and see Fraile-Ramos et al.,
2007). Re-expression of an siRNA-resistant VPS4B construct
rescued virus release and restored viral titers to 60% of the
wild-type control levels (compare lanes 2 and 3). In contrast,
expression of a siRNA-resistant VPS4B construct that lacked
ATPase activity failed to rescue virus budding (lane 4). Indeed,
expression of the inactive VPS4BK180Q mutant resulted in an
even lower viral titer than the siRNA-depleted control alone
(lane 2), presumably because the VPS4BK180Q mutant domi-
nantly inhibited all residual VPS4 function (Martin-Serrano
et al., 2003; Strack et al., 2003; von Schwedler et al., 2003).
Thus, this new VPS4 depletion/reconstitution assay could be
used to analyze the activity of mutant VPS4B proteins without
confounding contributions from endogenous human VPS4 pro-
teins, and the assay was therefore used to test the functional
importance of the VPS4B MIT MIM1 and MIM2 binding surfaces
in HIV budding.
An inactivating point mutation in the VPS4BMIM1 binding sur-
face (Leu66Asp, which is equivalent to the VPS4A Leu64Asp
mutation) reduced HIV release and titer 3-fold, as compared
with the wild-type VPS4B protein (Figure 6, compare lanes 3
and 5). Similarly, an inactivating point mutation in the VPS4B
MIM2 binding surface (Ala15Asp, which is equivalent to the
VPS4A Val13Asp mutation) resulted in an 2-fold reduction in
HIV release and titer (compare lanes 3 and 6). Furthermore, si-
multaneous mutation of both MIM1 and MIM2 binding sites re-
duced levels of HIV-1 release and titer 10-fold (compare lanes
3 and 7), to nearly the same level as that seen in the absence
of any exogenous VPS4B (compare lanes 2 and 7). Control ex-
periments again showed that all of the different VPS4B proteins
were expressed at similar levels, indicating that none of the mu-
tations acted by destabilizing the protein (panel 1, compare lanes
3–7). We conclude that the VPS4BMIM1 andMIM2 binding sites
both contribute to the efficiency of HIV-1 budding, and that
VPS4B is essentially inactive when both MIM binding sites are
mutated.
DISCUSSION
Our studies reveal that in addition to their well-characterized
MIM1 binding interactions, MIT domains bind a second class of
sequence motifs, which we term MIM2 elements. The structure
of the VPS4A MIT-CHMP6166–181 complex reveals that MIM2 el-
ements bind as extended strands in the groove between VPS4A
MIT helices 1 and 3, and that conserved residues within the
CHMP6MIM2elementmakea series of important contacts along
thegroove. Importantly, theCHMP6MIM2element is required for
efficient lysosomal degradation of ferroportin in response to
hepcidin treatment, demonstrating that this element is essential
for the MVB sorting of specific membrane protein cargoes.
MIM2 Elements in Other Proteins
MIT domains are found in both ESCRT and non-ESCRT proteins,
and MIT-MIM1 interactions continue to be documented in
increasing numbers (Hurley and Yang, 2008; Tsang et al.,
2006). Similarly, there are indications thatMIT-MIM2 interactions
may also be widespread. For example, VPS4B MIT-MIM2
interactions are required for efficient HIV budding, even though
Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc. 67
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Hepcidin-Induced Lysosomal Degradation
of Ferroportin
(A) Western blot analyses showing efficient siRNA
depletion of endogenousCHMP6 protein (top blot,
compare lanes 1 and 2), without changes in ferro-
portin-GFP (FPN) or a-tubulin levels (bottom two
blots).
(B) Western blot analyses of hepcidin-induced fer-
roportin-GFP downregulation in the presence of
wild-type and mutant CHMP6 proteins. Left
panels (controls) show ferroportin levels (middle
blot) in the absence (-) or presence (+) of hepcidin
treatment of cells expressing wild-type and
mutant CHMP6-Myc proteins (top blot) and en-
dogenous CHMP6 (control siRNA). Right panels
show the same experiment, but with depletion of
endogenous CHMP6, so that only the exogenous,
siRNA-resistant CHMP6-Myc proteins were pres-
ent. Integrated intensities were normalized to the
untreated control and are shown below each
band. Note that ferroportin-GFP levels decreased
2.3-fold upon hepcidin treatment in the presence
of wild-type CHMP6-Myc (compare lanes 7 and
8), but did not decrease in the presence of
CHMP6-Myc proteins with inactivating MIM2
point mutations (L170D and V173D).
(C and D) Epifluorescence and differential interfer-
ence contrast (DIC) images (C) and quantification
(D) showing the effects of hepcidin treatment
and CHMP6 mutations on ferroportin-GFP levels.
Samples 1–12 correspond to the equivalent sam-
ples in panel (B). Note that the data again show
that wild-type CHMP6-Myc supports efficient
hepcidin-induced ferroportin-GFP downregula-
tion (compare samples 7 and 8, 4.2-fold reduc-
tion), whereas the Myc-CHMP6 MIM2 mutants
do not (compare samples 9 and 11 to 10 and
12). Scale bar, 20 mm. DIC images of the hepci-
din-treated cells are provided for reference in the
lower row of panel (C). Quantifications presented
in (D) show the average fluorescence/cell from
two data sets (one blinded) of >100 cells each.
Error bars indicate standard deviations.CHMP6 is not required for this process, indicating that the
VPS4A MIT-CHMP6 MIM2 interaction is not the only biologically
relevant MIT-MIM2 interaction. Conceivably, HIV-1 buddingmay
instead involve the use of CHMP4 MIM2 elements. All three
CHMP4 family members also have identifiable MIM2 elements,
which are analogous to the CHMP6 MIM2 element in that (1)
the CHMP6 and CHMP4 MIM2 motifs reside at equivalent inter-
nal positions, (2) the CHMP4 MIM2 elements also bind VPS4A
MIT, albeit with lower affinities than the CHMP6 MIM2 element
(Table S1), and (3) the isolated CHMP4 MIM2 elements bind
more tightly than their full-length proteins, again indicating that
the full-length proteins likely adopt autoinhibited conformations.
We have also identified several other ESCRT-associated
proteins, including IST1, that contain functional MIM2 motifs
(M. Bajorek, E.M., J.J.S, S.G. Morham, M. Babst, and W.I.S.,
unpublished data; E.M., J. McCullough, S.P. Gygi, S.G. Morham,
and W.I.S., unpublished data). The VPS4A MIT-CHMP6166–181
68 Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc.structure, together with sequence analyses of the CHMP6,
CHMP4A-C, and IST1 MIM2 elements, suggests a core consen-
sus sequence of (L/V)Px(V/L)P (where [x] denotes a variable,
but hydrophilic, residue). Flanking CHMP6 residues, including
Glu176 and Leu178, can also make favorable interactions. In fu-
ture studies, it will therefore be important to identify and analyze
additional MIM2 elements to discern the absolute optimal MIT
binding sequence or sequences.
The VPS4 adaptor IST1 is of particular interest because
this protein contains MIM1 and MIM2 elements that can bind
VPS4A MIT simultaneously, creating a particularly high-affinity
interaction (M. Bajorek, E.M., J.J.S, S.G. Morham, M. Babst,
andW.I.S., unpublished data). Yeast Ist1p inhibits Vps4p assem-
bly in vitro (Dimaano et al., 2008), and we speculate that the pro-
tein may also serve to release CHMP protein substrates from
VPS4 MIT domains, which could explain why IST1 needs to
bind with high affinity and uses both types of MIM element.
Developmental Cell
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mains can bind MIM1 and MIM2 elements simultaneously, and
we have observed that this is true even when the MIM elements
are presented by different proteins (not shown). Hence, it ap-
Figure 6. The VPS4B MIT MIM1 and MIM2 Binding Surfaces Both
Contribute to Efficient HIV-1 Budding and Replication
Western blots 1 and 2 show simultaneous siRNA depletion of endogenous
VPS4A and VPS4B (compare lanes 1 and 2) and re-expression of exogenous
siRNA-resistant wild-type and mutant VPS4B proteins (blot 1, lanes 3–7).
Western blot 3 shows an a-tubulin loading control. Western blots 4 and 5
show levels of the viral Gag protein and its processed MA and CA products
in the cytoplasm (Cell, panel 4; note that all cells were transfected with a pro-
viral HIV-1 expression construct) and released as viral particles (Virus). Panel 6
shows viral titers, as assayed in single-cycle replication assays of the culture
supernatants. The experiment shows that simultaneous depletion of both
human VPS4 isoforms blocks HIV-1 release and infectivity (panels 5 and 6,
compare lanes 1 and 2), that reintroduction of a wild-type, siRNA-resistant
VPS4B protein construct significantly rescues virus release and titer (compare
lanes 2 and 3), and that virus release and titer are inhibited by the VPS4B
K180Q (lane 4, positive control), L66D (lane 5, inhibited MIM1 binding), A15D
(lane 6, inhibited MIM2 binding) and L66D,A15D (lane 7, inhibited MIM1 and
MIM2 binding) mutants.pears likely that the ability to engage both MIM1 and MIM2 ele-
ments is a general property of MIT domains. This multivalent
binding capability provides a potential rationale for the unusual
asymmetry of the MIT three-helix bundle in which helices 1
and 3 are displayed at right angles to the central helix 2 (Scott
et al., 2005b; Takasu et al., 2005). This geometry creates a shal-
low groove between helices 2 and 3 that can bind amphipathic
MIM1 helices, and a deeper groove between helices 1 and 3
that is better suited to binding the extended strand of the
MIM2 element. It will be of interest to learn whether the third,
shallow groove between helices 1 and 2 can also be used to
bind a third class of target proteins.
MIM2 Elements Contribute to VPS4 Recruitment
A specific point mutation in the VPS4A MIM2 binding site in-
hibited recruitment of VPS4AK173Q to endosomal class E com-
partments, which indicates that MIT-MIM2 interactions help
recruit VPS4 proteins to ESCRT-III assemblies. Although
interactions between isolated VPS4 MIT domains and ESCRT-
III subunits are relatively weak, we envision that four different
phenomena likely contribute to creating high-affinity VPS4 bind-
ing in vivo. First, conformational changes in ESCRT-III subunits
that accompany polymerization likely ‘‘unmask’’ VPS4MIT bind-
ing sites that are autoinhibited in the monomeric proteins (Lata
et al., 2008; Lin et al., 2005). This idea is supported by our obser-
vation that VPS4 MIT domains bind less tightly to the full-length
CHMP6 and CHMP4 proteins than to their isolated MIM2
elements. We note that a similar affinity enhancement is not
observed for C-terminal MIM1 elements, which implies that
ESCRT-III autoinhibition protects the internal MIM2 elements,
but not the terminal MIM1 elements. Second, copolymerization
of ESCRT-III may bring MIM1 and MIM2 elements from different
proteins into close juxtaposition, allowing individualMIT domains
to engage both elements simultaneously, thereby increasing
binding affinity (seeFigure 7). This idea is supportedbyour obser-
vations that MIT domains can bind MIM1 and MIM2 elements
simultaneously (M. Bajorek, E.M., J.J.S, S.G. Morham,M. Babst,
andW.I.S., unpublished data; and data not shown), and that both
MIMbinding surfacesare required to recruit VPS4 toclassEcom-
partments. Third, copolymerization of ESCRT-III subunits to cre-
ate an array of immobilized MIM elements should dramatically
enhance the binding avidity of the oligomeric VPS4 protein.
Finally, the LIP5/Vta1 activator can bind both VPS4 and
ESCRT-III subunits and therefore likely helps tether the enzyme
to the ESCRT-III lattice (Azmi et al., 2006, 2008; Lottridge et al.,
2006; Scott et al., 2005a; Shim et al., 2008; Xiao et al., 2008)
(note that this interaction was omitted from Figure 7 for clarity).
Possible Mechanisms for VPS4 Action
Like VPS4, several other AAA ATPases also initially recognize
their substrates by binding small C-terminal epitope ‘‘tags’’ on
their target proteins. Prominent examples of this interaction
include the recognition of tubulin tails by the microtubule sever-
ing enzyme spastin (Roll-Mecak and Vale, 2008; White et al.,
2007) and the recognition of terminal ssrA (and other) tags by
bacterial translocators of the Clp family. Extensive structural
and biochemical analyses of the translocators have established
that substrates are initially bound by a substrate recognition
domain (or separate protein), transferred to a binding site within
Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc. 69
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‘‘pulled’’ through the central pore by the ATP-dependent mo-
tions of central loops, which change conformation in response
to ATP binding and hydrolysis (reviewed in Licht and Lee,
2008). We previously suggested that Vps4 might remove sub-
units from the assembled ESCRT-III lattice by functioning in an
analogous fashion: by first binding the MIM tags on individual
ESCRT-III subunits, then transferring them into the central
pore, and then using the energy of ATP hydrolysis to pull the sub-
units out of the lattice. Although this idea is still speculative, it is
supported by our observation thatmutations in the central Pore 1
motif of VPS4 inhibit HIV budding (Scott et al., 2005a), and by the
recent report of a second, conserved internal ESCRT-III se-
quence element that may represent the VPS4 pore binding site
(Shim et al., 2008).
As noted earlier, a recent study showed that overexpressed
CHMP4 proteins can form concentric rings that surround the
bases of membrane tubules that extrude out from the plasma
membrane (Hanson et al., 2008). This observation suggests
that native ESCRT-III lattices may also consist of concentric
circular filaments that surround sites of vesicle extrusion,
virus budding, or both. Combining these models for VPS4 and
ESCRT-III function leads to a plausible scenario in which VPS4
and ESCRT-III might work together to produce the constriction
necessary for vesicle extrusion and/or membrane fission (Fig-
ure 7). Specifically, we envision that copolymerization of different
classes of ESCRT-III subunits into concentric circular filaments
would expose arrays of MIM1 and MIM2 sites and create high-
affinity VPS4 binding sites. VPS4 could then act as a disassembly
chaperone by removing individual ESCRT-III subunits from
the filaments. Subsequent ring reclosure would reduce the diam-
eter of the circular filament or filaments, creating a constricting
force on the encircled cargoes and helping to drive vesicle
extrusion and neck closure. Future studies will be necessary to
distinguish this model from alternatives in which the ESCRT-III
lattice could help create vesicles by other means, for example
by functioning as a membrane bending machine or by constrict-
ing the neck as a single continuously sliding helical filament.
EXPERIMENTAL PROCEDURES
Expression Constructs and Plasmids
Expression constructs are summarized in Table S3 and its footnotes.
Protein Expression and Purification
VPS4A MIT Expression and Purification
Recombinant VPS4AMIT (VPS4A residues 1–84) and VPS4AMITL64D were pu-
rified as described previously (Scott et al., 2005b; Stuchell-Brereton et al.,
2007). GFP-VPS4A MITV13D was expressed in BL21 (DE3) codon+ (RIPL)
E. coli cells in autoinduction media ZYP-5052 (Studier, 2005) at 37C for 5 hr,
then transferred to 23C for 16 hr. Subsequent steps were at 4C except where
noted. Cells were lysed by sonication and incubation in lysis buffer (50mM Tris
HCl [pH 8.0], 150 mMNaCl, and 2 mM b-ME) containing lysozyme (1.0 mg/ml),
deoxycholate (0.125%), and protease inhibitors (Sigma). Clarified lysate was
bound to a GSTPrep column (GE Healthcare), washed with lysis buffer, and
eluted with lysis buffer supplemented with 20 mM reduced glutathione. The
GST domain was removedwith TEV protease (50 mg/ml) during dialysis against
4 liters of lysis buffer (100 mM NaCl, 16 hr at 23C). The protein was concen-
trated and purified further by gel filtration on a Superdex 75 column (GEHealth-
care). Protein fractionswere pooled, concentrated, and passed over a glutathi-
one column to remove residual GST. TEV cleavage left two nonnative residues
at the N terminus of VPS4A MIT (Gly-His) not included in our numbering
scheme. The expected mass was confirmed by mass spectrometry.
Synthesis and Purification of CHMP6166–181 Peptides
Unlabeled CHMP6166–181 peptide was prepared by solid phase synthesis and
purified by reversed phase HPLC. 13C/15N CHMP6166–181 was expressed as
a (His)10TrpDLE peptide fusion in isotopic
13C- and 15N-labeled M9 minimal
media, purified from inclusion bodies under denaturing conditions, cleaved
with cyanogen bromide to remove the TrpDLE fusion, and repurified by
reversed phase HPLC (Stuchell-Brereton et al., 2007). Expected peptide
masses were confirmed by mass spectrometry and final peptide concentra-
tions were determined by amino acid analyses.
Biosensor Binding Assays
Biosensor binding experiments were performed as previously described us-
ing BIACORE 2000 and 3000 instruments (Stuchell-Brereton et al., 2007).
Briefly, GST-CHMP6, -CHMP4A, -CHMP5, and -CHMP1B proteins and mu-
tants were expressed and captured directly from BL21 (DE3) codon+ (RIPL)
E. coli extracts onto anti-GST antibody-derivatized CM5 sensor chips. Pure
VPS4 MIT proteins were diluted at the designated concentrations in binding
buffer and injected in triplicate (50 ml/min, 20C), and binding data were col-
lected at 2 Hz during the 30 s association and dissociation phases (see
Figure 1A). All interactions reached equilibrium rapidly and dissociated
within seconds during the dissociation phase, and binding constants were
obtained by fitting the equilibrium responses to 1:1 binding models (e.g.,
see Figure 1B).
NMR Sample Preparation
Samples used for NMR structure determination were prepared in a buffer con-
taining 25mMsodiumphosphate (pH 5.75), 50mMNaCl, 1.0mMEDTA, 40 mM
sodium azide, 90%H2O, and 10%D2O. The following NMR samples were pre-
pared: (1) 1.4 mM uniformly 15N-/13C-labeled VPS4A MIT + 1.8 mM unlabeled
CHMP6166–181 (NMR structure of bound VPS4A MIT and identification of inter-
molecular nuclear Overhauser enhancements (NOEs), KD = 5.8 mM, 98.5%
Figure 7. Model for VPS4 Recruitment and
ESCRT-III Filament Constriction
Schematic model showing how different ESCRT-III
subunits (blue and green) could coassemble into
concentricrings thatdisplayC-terminalMIM1 (green)
and internal MIM2 (blue) elements, thereby creating
a high-affinity VPS4 binding surface (orange, with
the three helices of the MIT domains in red, orange,
and yellow). Recruited VPS4 ATPases could then re-
move individual ESCRT-III subunits, constricting the
ringsaboutcargoes (red)and therebyhelpingtodrive
vesicle extrusion and neck closure (see text for full
details). We note that six molecules of the Vps4 acti-
vator, Vta1p/LIP5, also bind the VPS4 beta domains
andmake additionalMIT-ESCRT-III interactions, but
forclarity theseadditional interactionsarenotshown.
70 Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc.
Developmental Cell
Structure and Functions of Vps4 MIT-MIM2 Complexes
Developmental Cell 15, 62–73, July 2008 ª2008 Elsevier Inc. 71occupancy), (2) 1.55 mM unlabeled VPS4AMIT + 1.22 mM uniformly 15N-/13C-
labeled CHMP6166–181 (NMR structure of bound CHMP6166–181 and identifica-
tion of intermolecular NOEs, 98.5% occupancy), (3) 1.0 mM uniformly 15N-la-
beled VPS4A MIT + 2.0 mM unlabeled CHMP6166–181 (isotropic
1JNH of bound
VPS4A MIT, KD = 5.8 mM, 99.5% occupancy), and (4) sample 3 + 3% (w/v)
C12E5 with C12E5:n-hexanol molar ratio of 1:0.85 (1JNH +
1DNH for bound
VPS4A MIT, KD = 5.8 mM, 99.5% occupancy; Ru¨ckert and Otting, 2000).
All complexes were in fast exchange.
Data Collection and Resonance Assignment
Chemical shift assignments were made using a standard suite of triple-reso-
nance NMR experiments (Cavanagh et al., 1996) recorded at 25C on Varian
Inova 600 or 800 MHz NMR spectrometers equipped with triple-resonance
1H,13C,15N cryogenic (600 MHz) or room temperature (800 MHz) probes.
Data were processed with FELIX 2004 (Felix NMR, Inc), and resonances
were assigned using standard approaches within the SPARKY program
(T.D. Goddard and D.G. Kneller, University of California, San Francisco).
Nearly complete resonance assignments were obtained for VPS4A MIT-
CHMP6166–181 (98% of the
1H and directly attached 13C/15N resonances)
and include 140 stereospecific assignments of prochiral methylene andmethyl
signals. All prolines were in trans conformations. One-hundred and forty back-
bone phi and psi torsion angles were estimated from 13Ca chemical shifts
using TALOS (Cornilescu et al., 1999). Unlabeled CHMP6166–181 (sample 1)
and unlabeled VPS4A MIT (sample 2) resonance assignments were critical
for interpretation of intermolecular NOEs. These assignments were obtained
from a combination of 2D F1/F2-13C15N filtered [1H,1H] NOESY (60 ms mix
time), 2D F1/F2-13C15N filtered [1H,1H] TOCSY (35, 70msmix times), and anal-
ysis of 2D [15N,1H] HSQC (Figure S1) and 2D [13C,1H] HSQCduring the titration.
Double-edited NOESY experiments were unnecessary owing to the small size
of the system.
Amide residual dipolar couplings, 1DNH, were obtained from 2D [
15N,1H]
IPAP-HSQC (Ottiger et al., 1998) or analysis of 2D [15N,1H] HSQC and TROSY
of isotropic and aligned samples 3 and 4, respectively. Only those amides in
regular a-helical regions were included in the final structure calculation and
included in Table 1.
Structure Calculations
Intramolecular and intermolecular NOEs were obtained using 3D
[1H,13C/15N,1H] NOESY and 3D F1-13C/15N-filtered [1H,13C/15N,1H] NOESY
experiments (60 ms mixing times). Intermolecular NOEs were obtained from
the F1-13C15N-filtered [1H,13C/15N,1H] NOESY while intramolecular NOEs
were obtained from the difference of 3D [1H,13C/15N,1H] NOESY and 3D
F1-13C15N-filtered [1H,13C/15N,1H] NOESY. NOE coordinates (1H,15N/13C,1H)
and intensities were obtained by using the tools in SPARKY and exported
into CYANA (Guntert, 2004) for structure calculations. NOEs were assigned
and structures calculated using the automated NOE assignment module im-
plemented in CYANA (Version 2.1). Intermolecular NOEs were manually
assigned and incorporated into the complex structure calculation. Final
CYANA calculations included a-helical hydrogen bond restraints, derived from
the preliminary structures.
The lowest-energy CYANA structures were further refined in XPLOR-NIH us-
ing a simulated annealing protocol that implements amide residual dipolar
coupling constraints. Structure statistics for the VPS4A MIT-CHMP6166–181
complex are summarized in Table 1. Structures were visualized and superim-
posed and figures made using PYMOL (DeLano Scientific).
Confocal Fluorescence Microscopy
Transfection and confocal fluorescence imaging of COS7 cells expressing
wild-type and mutant GFP-VPS4A mammalian expression constructs were
performed as previously described (Stuchell-Brereton et al., 2007).
Ferroportin Downregulation Assays
CHMP6 Depletion and Reconstitution
HEK293T cells were transfected with nonspecific or CHMP6 siRNA oligonucle-
otides at final concentrations of 50–100 nM using OligofectAMINE (Invitrogen)
as previously described (De Domenico et al., 2007; Langelier et al., 2006).
Twenty-four to forty-eight hours posttransfection, cells were trypsinized and
plated onto sixty-millimeter plates without or with coverslips (for western orfluorescence analyses, respectively). Twenty-four hours later, the cells were
cotransfected with five micrograms pEGFP-N1-FPN and five micrograms
wild-type or mutant siRNA-resistant CHMP6 expression constructs using Nu-
cleofector technology (Amaxa) according to the manufacturer’s directions.
After an additional 18 hr, cells were incubated in the presence of cyclohexi-
mide (75 mg/ml) for 2 hr followed by incubation ±1 mg/ml hepcidin for 1 hr prior
to epifluorescence analysis. Fluorescent images were captured on an Olym-
pus BX51 microscope using an Olympus U-CMAD-Z camera and a 603/
1.30 NA oil-immersion objective lens. Images were acquired using Picture
Frame 2.5 software (Olympus America).
Western Blot Analyses
Western analyses were conducted in the same way, but with incubation with
or without hepcidin for 4 hr. Cell lysates were prepared as described previously
(De Domenico et al., 2007), and samples were normalized for the total protein
concentration using the bicinchoninic acid assay (Pierce) prior to loading.
Western detection used either anti-GFP (1:10,000, ab6556; Abcam); mouse
anti-tubulin (1:1000; GeneTex); rabbit anti-CHMP6 (1:1000; Covance), or
mouse anti-Myc (1:1000; Abcam), followed by either peroxidase-conjugated
goat anti-mouse IgG (1:10,000; Jackson ImmunoResearch Laboratories) or
peroxidase-conjugated goat anti-rabbit IgG (1:10,000; Jackson ImmunoRe-
search Labs). Blots were scanned and quantified using Quanti One software
(BioRad).
Quantification of Average Ferroportin-GFP Fluorescence
Average fluorescence per cell was calculated with ImageJ (http://rsbweb.nih.
gov/) software. Individual cells were outlined in freehand mode and the back-
ground-corrected average fluorescence for each condition was calculated
from two separate experiments (>100 cells each, one blinded).
siRNA Depletion of VPS4 and HIV-1 Release Assays
HEK293T cells were seeded at 2.53 105 cells per well in a 6-well plate and in-
cubated for 24 hr (37C, 5%CO2). siRNAs specific for VPS4A (sense: 50 CCGA
GAAGCUGAAGGAUUATT; underline denotes deoxynucleotides) and VPS4B
(sense 50-CCAAAGAAGCACUGAAAGATT) were transfected using Lipofect-
amine RNAi MAX (Invitrogen) at a concentration of 20 nM according to the
manufacturer’s instructions. Transfected cells were incubated for 24 hr and
then fresh media was added. Cells were cotransfected a second time with
the same VPS4 siRNAs (20 nM each), together with the siRNA-resistant
VPS4B mammalian expression vectors and the HIV-1 R9 proviral expression
vector (0.5 mg/well each), and incubated for 48 hr. Cytoplasmic extracts and
virus-containing supernatants were harvested and used for infectivity assays
or western blotting as described previously (Garrus et al., 2001). Briefly, titers
were determined in triplicate using single-cycle MAGIC assays in HeLa P4
cells. Gag-derived proteins in cytoplasmic and viral lysates were detected
by western blots using rabbit anti-CA and MA primary antibodies at 1:3000;
VPS4 protein levels in cell lysates were detected by western blotting with rab-
bit anti-VPS4A and VPS4B polyclonal antibodies at 1:1000 (von Schwedler
et al., 2003); and a-tubulin controls were detected with a mouse anti-a-tubulin
antibody (1:1000, DM1A, Sigma). Bound primary antibodies were detected
using donkey anti-rabbit IgG IR Dye 800 (Rockland) and goat anti-mouse
IgG Alex 680 conjugates (Invitrogen) at 1:10,000 and were visualized on an
Odyssey scanner (software version 3.0, LI-COR).
ACCESSION NUMBERS
Coordinates and chemical shift assignments have been deposited with the
Protein Data Bank, with accession code 2k3w.
SUPPLEMENTAL DATA
Supplemental Data include two figures and three tables and can be
found online at http://www.developmentalcell.com/cgi/content/full/15/1/62/
DC1/.
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